Drug Profile
Atogepant - AbbVie
Alternative Names: AGN 241689; AQUIPTA; MK 8031; QULIPTALatest Information Update: 18 Apr 2024
Price :
$50
*
At a glance
- Originator Merck AG
- Developer AbbVie; Allergan
- Class Amides; Antimigraines; Fluorinated hydrocarbons; Monoclonal antibodies; Piperidines; Pyridines; Pyrroles; Small molecules; Spiro compounds
- Mechanism of Action Calcitonin gene-related peptide receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Migraine
Most Recent Events
- 15 Apr 2024 Efficacy and adverse events data from a phase III trial in Migraine released by AbbVie
- 25 Mar 2024 Phase-III clinical trials in Migraine in United Kingdom (PO, Tablet) prior to March 2024 (NCT06241313)
- 22 Feb 2024 AbbVie completes in a phase I pharmacokinetic trial (In Volunteers) (PO, Tablet) in USA (NCT05892757)